Welcome to the Translocation Renal Cell Carcinoma Website at Johns Hopkins

This site is dedicated to patients with a subgroup of renal cell carcinoma and other cancers that involve chromosome translocations involving TFE3 or TFEB genes. Other names for these neoplasms in the literature include Xp11 translocation renal cell carcinoma, TFE3 rearranged renal cell carcinoma, Xp11 translocation PEComa, melanotic Xp11 translocation cancer, t(6;11) translocation renal cell carcinoma, and TFEB rearranged renal cell carcinoma, and MiT family translocation carcinoma. These neoplasms were originally described at Johns Hopkins by Dr. Pedram Argani, M.D., Professor of Pathology and Oncology, who maintains this site.

Drs. Argani and Nguyen

The purpose of this site is to provide a resource to patients with translocation renal cell carcinomas and their families. Included in this site are educational materials, links to the latest research on these neoplasms, and opportunities to contribute to the understanding of these neoplasms. We hope this site is useful to patients and their families.

Argani Cimino Mathews microscope landscape

Get a Second Opinion

An accurate diagnosis is essential to ensure that the correct and most effective treatment is given. Getting a pathology second opinion on a diagnosis can reverse a diagnosis or alter the treatment plan.

Slide7

Under the Microscope

Do you wonder what TRCC look like under the microscope? See examples of what a pathologist sees when looking at slides of TRCC.

Microscope

Timeline of Discoveries

The Translocation Renal Cell Carcinoma neoplasms were first described by Dr. Argani at Johns Hopkins in 2001. View the timeline of research discoveries since then.

80

Total number of cases of t(6;11) RCC reported in world literature

40%

Of pediatric renal cell carcinomas are XP11 translocation RCC

2001

The year that TRCC tumors were first described at Johns Hopkins